Syntal Capital Partners LLC Buys New Holdings in Regeneron Pharmaceuticals Inc (REGN)

Syntal Capital Partners LLC bought a new position in shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) during the 4th quarter, according to its most recent disclosure with the SEC. The fund bought 1,000 shares of the biopharmaceutical company’s stock, valued at approximately $375,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Fieldpoint Private Securities LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $130,000. Vident Investment Advisory LLC bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $200,000. Virtu KCG Holdings LLC bought a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth about $206,000. Moors & Cabot Inc. bought a new position in shares of Regeneron Pharmaceuticals in the 3rd quarter worth about $217,000. Finally, People s United Financial Inc. raised its position in shares of Regeneron Pharmaceuticals by 656.7% in the 2nd quarter. People s United Financial Inc. now owns 454 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 394 shares in the last quarter. 66.63% of the stock is currently owned by hedge funds and other institutional investors.

Shares of Regeneron Pharmaceuticals Inc (NASDAQ REGN) opened at $371.53 on Friday. The company has a debt-to-equity ratio of 0.12, a quick ratio of 3.07 and a current ratio of 3.63. The company has a market capitalization of $39,889.95, a P/E ratio of 33.74, a price-to-earnings-growth ratio of 1.43 and a beta of 1.53. Regeneron Pharmaceuticals Inc has a twelve month low of $340.09 and a twelve month high of $543.55.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, topping analysts’ consensus estimates of $3.83 by $0.16. The firm had revenue of $1.50 billion during the quarter, compared to analyst estimates of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. The company’s revenue for the quarter was up 23.0% on a year-over-year basis. During the same period in the previous year, the company posted $3.13 EPS. sell-side analysts predict that Regeneron Pharmaceuticals Inc will post 13.55 earnings per share for the current fiscal year.

Several research analysts have recently weighed in on the company. Barclays lowered Regeneron Pharmaceuticals from an “equal weight” rating to an “underweight” rating and lowered their price objective for the stock from $450.00 to $395.00 in a research report on Friday, October 20th. Canaccord Genuity reissued a “buy” rating on shares of Regeneron Pharmaceuticals in a research report on Monday, October 16th. Oppenheimer reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, September 27th. JPMorgan Chase & Co. reissued a “hold” rating on shares of Regeneron Pharmaceuticals in a research report on Tuesday, November 28th. Finally, Zacks Investment Research raised Regeneron Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, November 14th. Two research analysts have rated the stock with a sell rating, fifteen have assigned a hold rating, eleven have assigned a buy rating and one has assigned a strong buy rating to the company. Regeneron Pharmaceuticals presently has a consensus rating of “Hold” and a consensus target price of $471.11.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.dispatchtribunal.com/2018/01/20/syntal-capital-partners-llc-buys-new-holdings-in-regeneron-pharmaceuticals-inc-regn.html.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply